Institute for Animal Health, Pirbright Laboratory, Surrey, UK.
Antiviral Res. 2012 Apr;94(1):25-34. doi: 10.1016/j.antiviral.2012.02.002. Epub 2012 Feb 11.
Protection against foot-and-mouth disease (FMD) using DNA technology has been documented for sheep and pigs but not for the highly susceptible species of cattle. Twenty-five Holstein Friesian cross-bred cattle were vaccinated twice, 21 days apart, with a DNA vaccine containing the capsid coding region (P1) along with the non-structural proteins 2A, 3C and 3D (pcDNA3.1/P1-2A3C3D) of O(1) Kaufbeuren alone or coated onto PLG (d,l-lactide-co-glycolide) microparticles. In some pcDNA3.1/P1-2A3C3D was also combined with an adjuvant plasmid expressing bovine granulocyte macrophage colony stimulating factor (GM-CSF). DNA vaccinations were administered intramuscularly with, or without, the use of electroporation and at 42 days post primary vaccination cattle received a protein boost of 146S FMD virus (FMDV) antigen and non-structural protein 3D. For comparison, four cattle were vaccinated with a conventional FMD vaccine and two more included as unvaccinated controls. Apart from those immunised with PLG microparticles all cattle were challenged with 10(5) TCID(50) cattle adapted O(1) Lausanne FMDV virus at day 93 post primary vaccination. All DNA vaccinated cattle regardless of regime developed good humoral and cell mediated responses prior to challenge. The best overall virus neutralising antibody, IFN-γ and clinical protection (75%) were seen in the cattle whereby the DNA was delivered by electroporation. In contrast, only 25% of cattle vaccinated with the DNA vaccine without electroporation were clinically protected. The addition of GM-CSF in combination with electroporation further improved the efficacy of the vaccine, as demonstrated from the reduction of clinical disease and virus excretions in nasal swabs. We thus demonstrate for the first time that cattle can be clinically protected against FMDV challenge following a DNA prime-protein boost strategy, and particularly when DNA vaccine is combined with GM-CSF and delivered by electroporation.
利用 DNA 技术预防口蹄疫(FMD)已在绵羊和猪中得到证实,但对于高度易感的牛种尚未见报道。25 头荷斯坦-弗里森杂交牛分两次接种 DNA 疫苗,间隔 21 天,疫苗包含 O(1) Kaufbeuren 型口蹄疫病毒衣壳编码区(P1)以及非结构蛋白 2A、3C 和 3D(pcDNA3.1/P1-2A3C3D),单独或包被在 PLG(聚乳酸-乙醇酸共聚物)微球上。在一些 pcDNA3.1/P1-2A3C3D 中还结合了表达牛粒细胞-巨噬细胞集落刺激因子(GM-CSF)的佐剂质粒。DNA 疫苗通过肌肉注射,或联合电穿孔,在初次免疫后 42 天,牛接受了 146S 口蹄疫病毒(FMDV)抗原和非结构蛋白 3D 的蛋白加强。为了比较,4 头牛用常规口蹄疫疫苗免疫,还有 2 头作为未免疫对照。除了用 PLG 微球免疫的牛外,所有牛都在初次免疫后 93 天接受了适应牛的 O(1) Lausanne 口蹄疫病毒 10(5)TCID(50)的挑战。所有 DNA 免疫牛无论采用何种方案,在攻毒前均产生了良好的体液和细胞介导免疫反应。在通过电穿孔递送 DNA 的牛中,观察到最佳的病毒中和抗体、IFN-γ和临床保护(75%)。相比之下,未经电穿孔接种 DNA 疫苗的牛中只有 25%具有临床保护。GM-CSF 的添加与电穿孔联合使用进一步提高了疫苗的效力,从减少临床疾病和鼻拭子中的病毒排出可以看出这一点。因此,我们首次证明,牛可以通过 DNA 初免-蛋白加强策略对 FMDV 挑战产生临床保护,特别是当 DNA 疫苗与 GM-CSF 联合使用并通过电穿孔递送时。